Best Immunotherapy Companies in Switzerland
The 66 best Immunotherapy companies in Switzerland in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: ADC Therapeutics.
- ResearchAndMarkets.com
- The Business Research Company
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Immunotherapy companies in Switzerland
| # | Company | Disclosed funding | Last round | Employees | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | ADC Therapeutics Developer of antibody-drug conjugates for the treatment of cancer indications | $641M | 61 mo ago | 50 | Stephen Freke Co-Founder & Director | 7 signals ▲40% Earnings · Announcements | 526 patents Patents concentrated in health & consumer products | 2 awards |
| 2 | Bright Peak Therapeutics Developer of small molecule-based therapeutic solutions for the treatment of cancer and autoimmune disease | $232M | 25 mo ago | 57 | Jeffrey Bode Co-Founder | — | 91 patents Engineered IL-2/IL-18 cytokine fusion proteins for targeted cancer immunotherapy | — |
| 3 | Alentis Therapeutics Developer of therapies for treating fibrosis, cirrhosis, and liver cancer | $184M | 19 mo ago | 38 | Thomas Baumert Founder & Board Member | 5 signals ▲400% Leadership | 35 patents Therapeutic anti‑claudin‑1 antibodies and bispecifics for liver/biliary cancers and fibrosis | — |
| 4 | Neurimmune Developer of antibody therapeutics for the treatment neurodegenerative diseases | $180M | 53 mo ago | 82 | Roger Nitsch CEO & President | — | 95 patents Antibody therapeutics and diagnostics targeting transthyretin amyloidosis and musculoskeletal diseases | — |
| 5 | Anaveon Developer of immunotherapies for treating cancers | $157M | 54 mo ago | 30 | — | — | 13 patents Engineered cytokine fusion proteins and PD‑1 antibody domains for immuno‑oncology therapeutics. | — |
| 6 | Nouscom Developer of viral-vector-based vaccines for the treatment of cancer | $152M | 27 mo ago | 37 | — | — | 129 patents Personalized and universal cancer vaccines using neoantigens and viral vector immunotherapies | — |
| 7 | Numab Developer of multispecific antibody therapeutics for inflammation and cancer | $150M | 17 mo ago | 78 | David Urech CEO | — | 38 patents Engineering bispecific and multispecific antibody formats for therapeutic targeting | — |
| 8 | Alexion Developer of therapies for patients with devastating and rare diseases | $133M | 96 mo ago | 1 | — | — | — | — |
| 9 | AC Immune Developer of antibodies, small molecules, and vaccines for Alzheimer’s disease and other neurodegenerative… | $120M | 29 mo ago | 156 | Andrea Pfeifer CEO | 8 signals ▲60% Earnings · Layoffs · Leadership | 1,305 patents Patents concentrated in chemistry & materials | — |
| 10 | Anokion Developer of therapeutic proteins to treat autoimmune and allergic diseases | $112M | 44 mo ago | 30 | — | — | 65 patents Patents concentrated in health & consumer products | — |
| 11 | iOnctura Developer of pharmaceuticals to treat cancer | $112M | 24 mo ago | 20 | Lars van der Veen Founder & CTO | — | 39 patents Patents concentrated in health & consumer products | — |
| 12 | ImmunOs Therapeutics Developer of immunotherapies for the treatment of cancer and autoimmune diseases | $102M | 21 mo ago | 31 | Christoph Renner Co-Founder & CMO | — | 33 patents Engineered HLA fusion proteins targeting CD47‑SIRPA immune checkpoint modulation | — |
| 13 | Memo Therapeutics Developer of antibodies for treating infectious diseases and cancer | $97M | 25 mo ago | 21 | — | — | 52 patents Therapeutic antibodies targeting BK virus and SIGLEC‑9, plus immunoreceptor gene recovery | 1 partnership |
| 14 | CDR-Life Developer of antibody therapeutics for the treatment of cancer | $76M | 50 mo ago | 58 | Christian Leisner CEO & Co-Founder | — | 63 patents Therapeutic antibodies and bispecific T‑cell engagers targeting cancer peptides and ocular diseases | 1 launch |
| 15 | NBE-Therapeutics Developer of antibody-drug conjugates for cancer | $66M | 77 mo ago | 21 | — | — | 154 patents Site-specific antibody‑drug conjugate technologies using anthracycline payloads | 1 job opening |
| 16 | Cytos Biotechnology Developer of novel immunotherapies for asthma treatment | $64M | 255 mo ago | 13 | Joost de Bruijn CEO | — | 420 patents Nucleic acid therapeutics and antibody engineering, including VLP delivery and protein purification | — |
| 17 | Metrio Pharm Clinical stage Biopharma developing small molecule immune modulator against chronic immune disorders | $50M | 56 mo ago | 19 | Thomas Christely CEO | — | — | — |
| 18 | Anergis Developer of vaccines against birch pollen allergy, ragweed and dust mites allergy | $49M | 122 mo ago | 11 | — | — | 60 patents Patents concentrated in health & consumer products | — |
| 19 | Delenex Antibody therapeutics for oncology and dermatological inflammatory diseases | $41M | 151 mo ago | — | Eric de La Fortelle ex-CEO | — | — | — |
| 20 | Polyneuron Developer of antibody catch technology for treatment antibody-mediated autoimmune diseases | $40M | 62 mo ago | 9 | — | — | — | — |
| 21 | Mabylon Developer of therapeutics for allergies and neurodegenerative diseases | $39M | 10 mo ago | — | Alcide Barberis CEO | — | 38 patents Therapeutic antibodies targeting allergens and ASC inflammasome proteins for allergy and inflammation treatment. | — |
| 22 | Amal Therapeutics Developer of therapeutic vaccine for cancer | $37M | 91 mo ago | 27 | Laetitia Devy-Dimanche Chief Executive Officer | — | 101 patents Intracellular delivery of cell‑penetrating peptide complexes for cancer immunotherapy | — |
| 23 | Calypso Biotech Developer of antibody-based therapeutics for the treatment of gastrointestinal diseases | $36M | 57 mo ago | 12 | — | — | 29 patents Therapeutic antibodies targeting IL‑15 cytokine and MMP‑9 protease for inflammatory disease treatment | — |
| 24 | Telormedix Biopharma company focused on evaluating and establishing role of innate immunity in treating cancer and… | $34M | 150 mo ago | 7 | — | — | 56 patents Topical imidazoquinoline immune agonists and phospholipid‑based drug delivery formulations. | — |
| 25 | Vaxxilon Developer of synthetic carbohydrate vaccines for drug-resistant infectious diseases | $33M | 82 mo ago | 17 | — | — | 31 patents Design of synthetic polysaccharide‑protein conjugate vaccines for bacterial pathogens | — |
| 26 | GlycoVaxyn Developer of bioconjugate vaccines to treat a range of bacterial infections | $32M | 207 mo ago | 21 | Michael Wacker Co-Founder | — | 147 patents Engineered bacterial glycoprotein and polysaccharide conjugate vaccines for infectious disease prevention | — |
| 27 | Vector BioPharma Developer of gene delivery platform to treat various disease conditions | $30M | 46 mo ago | 39 | Lorenz Mayr Co-Founder | — | 7 patents Targeted adenoviral gene‑delivery platforms for immune‑cell therapies and vector production | — |
| 28 | 4-Antibody Antibody discovery and optimization platform for drug development | $21M | 233 mo ago | 42 | — | — | 8 patents Antibody and binding protein discovery/engineering using nucleic acid sequencing and modified lymphocytes | — |
| 29 | Virometix Vaccines and immunotherapeutic drugs for the prevention and treatment of infectious diseases (both bacterial… | $19M | 7 mo ago | 15 | Anna Sumeray CEO | — | 41 patents Peptide-based vaccine antigens and lipopeptide VLP platforms for RSV and pneumococcus | — |
| 30 | Engimmune Therapeutics Developer of T-cell receptor-based therapeutics for cancer and autoimmune diseases | $16M | 49 mo ago | 25 | Sai Reddy Co-Founder | — | — | — |
| 31 | AmVac Vaccine developer for the treatment of infections and urogenital conditions | $15M | 156 mo ago | 11 | Ali Pashazadeh CEO | — | 29 patents Recombinant negative‑strand RNA viral vectors for heterologous protein expression and RSV semi‑live vaccines | — |
| 32 | Sellas Life Sciences Developer of therapeutics for the treatment of cancer | $14M | 70 mo ago | 17 | — | — | — | — |
| 33 | Glycart Biotechnology Antibody products for cancer | $14M | 270 mo ago | — | Pablo Umana Founder | — | 193 patents Engineered therapeutic antibodies and Fc-modified antigen binders for cancer immunotherapy | — |
| 34 | Kenta Biotech Developing human monoclonal antibodies for the prevention and treatment of bacterial and viral infections | $10M | 207 mo ago | 11 | — | — | 46 patents Therapeutic and diagnostic human monoclonal antibodies for S. aureus alpha‑toxin and P. aeruginosa LPS serotypes | — |
| 35 | NovaGo Therapeutics Company developing human derived antibodies for cerebral stroke and spinal cord injury | $10M | 87 mo ago | 5 | Martin Schwab Founder & President | — | 14 patents Therapeutic anti‑Nogo‑A antibodies for CNS injury and neuro‑degenerative disease treatment | — |
| 36 | CT Atlantic Cancer therapeutics using humanized monoclonal antibodies | $9M | 209 mo ago | 3 | — | — | 18 patents Therapeutic antibodies targeting tumor-associated antigens, notably MAGEA3 cancer vaccines | — |
| 37 | Vaximm Developing active immunotherapies (vaccines) for patients suffering from cancer. | $8M | 185 mo ago | 7 | — | 4 signals Contracts | 148 patents VEGFR-2‑targeted DNA vaccine platforms for cancer immunotherapy | — |
| 38 | MaxiVAX Developing immunotherapies for treating cancer | $5M | 47 mo ago | 8 | Bernard Mach Co-Founder & Executive Chairman | — | 35 patents Implantable drug‑delivery capsules and immortalized myoblast cell platforms for therapeutic protein production | — |
| 39 | Relief Therapeutics Developer of drugs for treating pulmonary and infectious diseases | $3M | 22 mo ago | 69 | — | 3 signals ▼70% M&A | — | — |
| 40 | Mymetics Virosome-based prophylactic vaccines for viral infections | $2M | 133 mo ago | 8 | — | — | 42 patents Oral virosome-based vaccine formulations for mucosal immunization | — |
| 41 | Redbiotec Multiprotein assemblies as prophylactic vaccines against infectious diseases | $2M | 138 mo ago | 12 | Corinne John Co-Founder | — | 42 patents HSV therapeutic vaccines and recombinant host cell production of casein proteins | — |
| 42 | MPC Developer of new generation of small molecules for cancer and degenerative diseases | $2M | 31 mo ago | — | Augustin Bettignies Co-Founder & Co-CEO | — | — | — |
| 43 | Laevoroc Oncology Developer of therapeutics for cancer | $1M | 61 mo ago | 4 | Thomas Mehrling Founder-CEO at Laevoroc | — | — | — |
| 44 | REMUUN Developer of therapeutic monoclonal antibodies | $170K | 15 mo ago | — | Richard Chahwan Founder & CEO | — | — | — |
| 45 | ABOLOGIX Developer of antibody therapeutics to treat non-Hodgkin´s lymphoma | $167K | 60 mo ago | — | Beat Imhof Co-Founder | — | — | — |
| 46 | NXI Therapeutics Developer of immunotherapies for autoimmune diseases and organ transplantation | $159K | 48 mo ago | 4 | Rajesh Jayachandran Co-Founder | — | — | — |
| 47 | BioCopy Developer of immunotherapies for tumor and autoimmune diseases | $116K | 92 mo ago | 27 | Niko Bausch Co-Founder | — | — | — |
Top 12 Immunotherapy companies in Switzerland
#1
Series C · Zurich, Zurich · founded 2009 · 15 employees$18.9Mraised▾
Virometix is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases. Rational molecular design, chemical synthesis and Virometix's proprietary Synthetic Virus-Like Particle platform technology allow for the rapid production and optimization of vaccine candidates with superior properties in terms of safety, efficacy and stability. Virometix Vaccines is a spin-out company from the University of Zurich.
- Nov 2025Series C$15M
- Jul 2020Series B$8M
- Sep 2017Series A$1.3M
- May 2017Series A$5.1M
#2
Series B · Schlieren, Zurich · founded 2015$38.7Mraised▾
Developer of therapeutics for allergies and neurodegenerative diseases. It offers antibody therapies for Peanut allergy, pollen allergy, ALS, neuroinflammation, and Alzheimer's disease.
- Aug 2025Series B$37M
- Sep 2024Grant (prize money)$1.5M
- May 2020Grant (prize money)$55.5K
- Dec 2019Grant (prize money)$55.1K
#3
Series C · Wadenswil, Zurich · founded 2011 · 78 employees$149.7Mraised▾
Developer of multispecific antibody therapeutics for inflammation and cancer. The company applies proprietary discovery and engineering platforms to generate antibody fragment-based candidates with tailored pharmacokinetic properties. Its pipeline includes first-in-class bispecific and multispecific drug candidates targeting inflammatory and oncological indications. The platform technology enables assembly of stable, highly potent antibody formats using modular building blocks. By leveraging scalable, reproducible engineering methods, the company accelerates therapeutic discovery and optimizes manufacturing characteristics.
- Jan 2025Series C$55M
- May 2021Series C$111M
- Mar 2020Series B$23.5M
- Dec 2019Series B$15.2M
#4
Series D · Basel, Basel Stadt · founded 2019 · 38 employees$184.3Mraised▾
Developer of therapies for treating fibrosis, cirrhosis, and liver cancer. They have developed a gene expression platform. Their drug candidates (monoclonal antibodies) target a cell surface protein, which is being investigated for liver disease and cancer. The products include ALE-F02, CLDN1 for Liver Fibrosis (F3/F4) and kidney fibrosis, and ALE-C04, CLDN1 for Hepatocellular Carcinoma (HCC), and Cholangiocarcinoma.
- Nov 2024Series D$181.4M
- Apr 2023Series C$105M
- Jun 2021Series B$67M
- Apr 2019Series A$12.3M
#5
Series C · Schlieren, Zurich · founded 2013 · 31 employees$102.5Mraised▾
Developer of immunotherapies for the treatment of cancer and autoimmune diseases. The company has an HLA-based pipeline that includes first-in-class immunotherapies for the treatment of cancer and autoimmune diseases. The Company´s lead product candidate, IOS-1002, is an HLA-based protein that blocks the activation of three different immunosuppressive receptors (also known as checkpoints) on innate and adaptive immune cells
- Sep 2024Series C$11M
- Jun 2022Series B$74M
- Dec 2019Series A$15.2M
- Oct 2018Series A—
#6
Series C · Basel, Basel Stadt · founded 2017 · 57 employees$232Mraised▾
Developer of small molecule-based therapeutic solutions for the treatment of cancer and autoimmune disease. The company is involved in the development of cytokines by using Enhanced Design and Combine (EDC) platform for immuno-oncology indications.
- May 2024Series C$90M
- Mar 2021Series B$107M
- Jul 2020Series A$35M
#7
Series B · Geneva, Geneva · founded 2017 · 20 employees$111.7Mraised▾
Developer of pharmaceuticals to treat cancer. The company is developing a pipeline of next-generation, precision molecules for oncology indications which include IOA-244 and IOA-359 for solid tumors, and hematological malignancies and IOA-289 for pancreatic cancer.
- Jun 2024Series B$85.9M
- Dec 2022Grant (prize money)$18.6M
- Nov 2022Series A$1.2M
- Sep 2022Conventional Debt$403.9K
#8
Series C · Schlieren, Zurich · founded 2012 · 21 employees$97.2Mraised▾
Developer of antibodies for treating infectious diseases and cancer. The company has developed its proprietary microfluidic single-cell molecular cloning and screening technologies for the production of antibodies. The company's lead candidate is used to treat infectious diseases.
- May 2024Series C$22.1M
- Nov 2023Series C$27.5M
- Feb 2022Series B$24.9M
- Dec 2021Grant (prize money)$11.4M
#9
Series C · Basel, Basel Stadt · founded 2015 · 37 employees$152Mraised▾
Developer of viral-vector-based vaccines for the treatment of cancer. It has product candidates which include Endovax, an antigen-less vaccine, is based on oncolytic viruses capable of infecting and replicating only in cancer cells and causing immunogenic cell death, thereby recruiting T cells at the tumor site and reactivating T cells exhausted in the tumor micro-environment. Exovax is a personalized patient-specific vaccine, based on viral vectors coding for strings of cancer neo-antigens to induce and expand cancer and patient-specific T cells.
- Mar 2024Series C$7.6M
- Nov 2023Series C$82M
- Nov 2017Series B$48.8M
- May 2016Series A$13.6M
#10
Public · Lausanne, Vaud · founded 2003 · 156 employees$119.8Mraised▾
Developer of antibodies, small molecules, and vaccines for Alzheimer’s disease and other neurodegenerative diseases. It has a diversified pipeline of drugs for Alzheimer’s disease, Parkinson’s, Down syndrome, and Glaucoma. The company has technology platforms, SupraAntigen and Morphomer which generate sensitive diagnostics, highly specific biologics and small molecule drugs.
- Dec 2023Post IPO—
- Sep 2022Grant (prize money)$500K
- Sep 2019Grant (prize money)—
- Dec 2018Post IPO$50M
#11
Public · Epalinges, Vaud · founded 2011 · 50 employees$641Mraised▾
Developer of antibody-drug conjugates for the treatment of cancer indications. The company's lead candidate is Zynlonta which is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. Other drug candidates include ADCT-602 for B-cell acute lymphoblastic leukemia (ALL), ADCT-901 for ovarian cancer, and triple-negative breast cancer, and more.
- May 2021Post IPO$50M
- Apr 2020Series E$115M
- Jul 2019Series E$25M
- Jun 2019Series E$76M
#12
Public · Geneva, Geneva · founded 2013 · 69 employees$2.8Mraised▾
Developer of drugs for treating pulmonary and infectious diseases. The company's lead candidate is RLF-100 a synthetic human vasoactive intestinal peptide (VIP) for respiratory indications. It is currently focused on COVID-19-induced severe lung injury and pulmonary sarcoidosis. Another drug candidate ACER-001 is being developed for the treatment of two rare and debilitating diseases including Urea cycle disorders and Maple syrup urine disease.
- Aug 2024Post IPO—
- Jun 2023Post IPO—
- Aug 2021Post IPO$16.4M
- Mar 2021Post IPO$10.8M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Immunology & Immunotherapy is moving in Switzerland
A read on the academic research around Immunology & Immunotherapy — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 856 Switzerland-affiliated papers.
- Karger Publishers183
- Ludwig Cancer Research75
- Roche58
- University of Zurich57
- University Hospital of Zurich57
- Immune system4→84
- Tumor microenvironment1→27
- Cancer immunotherapy3→26
- Immune checkpoint1→17
- Cytotoxic T cell4→19
- Immune system11→104
- Cancer4→43
- Oncology5→40
- Tumor microenvironment3→37
- Internal medicine6→34
- Immune system6→34
- Cancer4→31
- Disease2→18
- Clinical trial1→16
- Melanoma3→12
Where immunology is researched across Switzerland
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.